AstraZeneca Results Presentation Deck
Liver,
kidney
Heart,
muscle
Rare Disease - R&D highlights
Innovative delivery platforms expanding genomic research
CNS
+
gene editing SAAVY™
‒‒‒‒‒‒‒‒‒‒
AAV
THERAPEUTICS
Y
protein TfR1 conjugate
delivery
JU
(JCR
Pharmaceuticals
CEO Opening Remarks
Azt
+
CRISPR non-viral
oligo-
nucleotide
non-viral
Financial Results
AAV
+
CRISPR
Oncology
ALXN2030 non-viral
(C3 siRNA)
AAV
2Pfizer
AAV
CRISPR
+LNP
BioPharmaceuticals
+
AAV
Pfizer
AAV
Rare Disease
Furthering our
genomic capabilities
CEO Closing Remarks
accelerating genomic
portfolio ambitions
with acquisition of Pfizer
AAV capsids
combining innovative
technologies with
LogicBio and AstraZeneca
partnering to access
novel gene delivery
technology
Acquisitions and collaborations complement existing AstraZeneca technologies
and increases genomic medicine portfolio >4x
SAAVYTM = proprietary adeno-associated virus capsid engineering platform; CRISPR = clustered regularly interspaced short palindromic repeats; C3 = complement protein 3; siRNA = short interfering RNA; LNP = lipid nanoparticle;
27 AAV = adeno-associated virus; CNS = central nervous system; TfR1 = transferrin receptor protein 1.
Note: Acquisition of Pfizer preclinical gene therapy programmes subject to customary regulatory clearances and other closing conditions.View entire presentation